A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination.

Trial Profile

A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2018

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary) ; Palbociclib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SPRING
  • Most Recent Events

    • 28 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top